New Clinical Study Demonstrates Benefits of RESPeRATE for Heart Failure Patients
Use of digital therapeutic device in 12-week crossover study improved exercise capacity, cardiac function and sleep disordered breathing
TEL AVIV, Israel, April 26, 2017 /PRNewswire/ -- 2breathe Technologies Ltd. with its wholly owned U.S. subsidiary Resperate Inc. announced, today, the publication of a new peer reviewed original article with the results from a 96 heart failure patients study. The independent study used the company's FDA-cleared hypertension treatment device, RESPeRATE. The study demonstrated that using RESPerATE during 12-weeks in the home setting can improve exercise capacity, left ventricular function, accompanied by a reduction in end-diastolic diameter of the left ventricle and attenuation of sleep disturbances, mainly central apnea.
The study was led by Professor Kalina Kawecka-Jaszcz, from the Department of Cardiology at the Jagiellonian University Medical College, Kraków, Poland in collaboration with Gianfranco Parati, Professor of Cardiovascular Medicine at the Univeristy of Milano-Bicocca and Head of Cardiology Department, S.Luca Hospital, Istituto Auxologico Italiano, Milan, Italy.
"Chronic heart failure has become one of the most widespread diseases and a principal cause of morbidity and mortality in aging societies, due to the high prevalence of its main causes, namely, hypertension and coronary heart disease," said Professor Parati, a world-leading cardiologist and expert in the arena of telemedicine and digital therapeutics. "These new study results are consistent with two earlier randomized controlled studies supporting the benefits of RESPeRATE as a novel component of cardiorespiratory rehabilitation programs in patients with CHF."
CHF affects about 5.7 million patients in the U.S alone and is the most widespread cause of hospitalization of patients over 65, with more than one million hospitalizations every year and total treatment costs amounting to $33 billion annually. About 91% of CHF sufferers have a medical history involving hypertension.
"The results of these independent studies on heart failure patients and sleep disordered breathing in particular, expand the growing body of scientific evidence that the benefits of RESPeRATE extend beyond hypertension," said Erez Gavish, co-founder/CEO of 2breathe technologies. "As a digital therapeutic device, RESPeRATE goes beyond patient monitoring to encourage compliance and offer a powerful non-drug therapeutic option that improves patient lives. It's a very exciting future."
About 2breathe Technologies Ltd.
Tel-Aviv-based 2breathe Technologies Ltd. and its wholly owned U.S. subsidiary Resperate Inc. is a pioneer in the development of digital therapeutic devices; first for hypertension and more recently for sleeplessness. The original product, RESPeRATE® Hypertension Therapy is the world's first FDA-cleared, non-pharmacological hypertension treatment device now used by hundreds of thousands of patients worldwide and is featured in the American Heart Association statement on non-pharmacological treatments. The new product, 2breathe: Sleep Inducer™, adopts RESPeRATE'S real-time coach guided-breathing technology for individuals who have difficulty sleeping. 2breathe was awarded the 2017 CES innovation award in the fitness, health and biotech category. For additional information, please visit www.resperate.com.
Company contact:
Erez Gavish
Co-Founder & CEO
Resperate Inc.
press@resperate.com
SOURCE 2breathe Technologies Ltd
Share this article